Summary & Overview
HCPCS J9334: Injection of Efgartigimod Alfa with Hyaluronidase, 2 mg
HCPCS Level II code J9334 denotes an injection of efgartigimod alfa combined with hyaluronidase-qvfc, billed per 2 mg unit. This code captures administration of a subcutaneous-capable biologic designed to modify immune-mediated conditions and is relevant to outpatient infusion centers, ambulatory clinics, and physician offices nationwide. Its use has implications for medical and pharmacy benefit adjudication, site-of-care determinations, and specialty drug management.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context and service setting, typical billing considerations associated with HCPCS Level II biologic codes, and the types of benchmarks and policy topics commonly reviewed alongside such codes (coverage policy alignment, billing guidance for site of service, and utilization monitoring).
This summary prepares clinical administrators, coding staff, and policy analysts to identify where J9334 appears on claims, understand its primary clinical application, and locate further details on reimbursement benchmarks and payer-specific policy updates. Data not available in the input is noted where applicable in downstream sections.
Billing Code Overview
HCPCS Level II code J9334 describes an injection of efgartigimod alfa with hyaluronidase-qvfc, with the billing unit defined as 2 mg. The service represents administration of a biologic therapy formulated with hyaluronidase to facilitate subcutaneous dispersion.
-
Service type: Injection, biologic agent
-
Typical site of service: Outpatient infusion or injection clinic, ambulatory care center, or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with generalized myasthenia gravis (gMG) who has inadequate response to standard therapies and is eligible for targeted immunomodulatory treatment. The patient presents to an infusion clinic or specialty ambulatory care center for administration of efgartigimod alfa with recombinant human hyaluronidase (formulated together for subcutaneous or facilitated subcutaneous delivery). Before treatment the clinician documents diagnosis, baseline strength and functional scales (e.g., Myasthenia Gravis Activities of Daily Living profile), current medications, and relevant laboratory studies (complete blood count, basic metabolic panel). The workflow includes nursing pre‑assessment, verification of medication and dose, consent and education about infusion‑related reactions, venous access or subcutaneous site preparation, administration per product instructions, post‑administration monitoring for adverse events (typically 30–60 minutes), and documentation of lot number, dose, and any immediate reactions. Treatment is commonly provided in an outpatient infusion center, specialty clinic, or hospital outpatient department. Billing uses HCPCS Level II code J9334 to report the efgartigimod alfa product with hyaluronidase component; appropriate modifiers are appended for service circumstances (e.g., multiple procedures, unusual services, or denial-related indicators).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified procedure |